Bafilomycin C1 is a macrolide antibiotic inhibitor of membrane V-ATPase (vacuolar-type H+-ATPase) enzymes. The V-ATPase proteins are ATP-dependent proton pump structures which are highly conserved across many different types of organisms, including eukaryotes, bacteria, fungi, nemotodes, and plants. Bafilomycin C1, as well as Bafilomycin A (sc-201550) and the other compounds of the family, demonstrates antibacterial and antinematodal properties. V-ATPases on the osteoclast bone-apposed plasma membrane are crucial for the process of bone resorption, and excessive resorption is correlated to syndromes of deficient bone material such as osteoporosis; V-ATPase inhibitors such as Bafilomycin C1 represent potential interventional agents upon this bone resorption.
1. Bowman, E.J., et al. 1988. Proc. Natl. Acad. Sci. U.S.A. 85: 7972-7976. PMID: 2973058
2. Rautiala, T.J., et al. 1993. Biochem. Biophys. Res. Commun. 194: 50-56. PMID: 8333864
3. Lacey, E., et al. 1995. Int. J. Parasitol. 25: 349-357. PMID: 7601593
4. Xu, J., et al. 2007. Histol. Histopathol. 22: 443-454. PMID: 17290355
Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2019 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.